Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activityLing Li, Jingxuan Chen, Yinrong Wu et al.|Bioorganic Chemistry|2021Cited by 40
Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agentsLing Li, Jianjun Chen, Huiting Zhao et al.|Bioorganic & Medicinal Chemistry|2022Cited by 16
Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activityHuiting Zhao, Jianjun Chen, Ling Li et al.|Bioorganic Chemistry|2022Cited by 14
Corrigendum to “Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity” [Bioorgan. Chem. 117 (2021) 105447]Ling Li, Yinrong Wu, Zichao Yang et al.|Bioorganic Chemistry|2024Cited by 0